Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Hematologic Malignancies

Part of Cancer

Subtypes of Hematologic Malignancies

Hematological malignancies 5 Hematological Malignancy 3 Polycythemia Vera 0

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hematologic Malignancies

29 trials tracked for Hematologic Malignancies: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 441 citations.

29Trials tracked

2Phase 3 & 4

0Recruiting

1With published results

Phase distribution

Phase 3 2 Phase 2 20 Phase 1 4 Other / NA 3

Phase 3 Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma Completed · 441 cited
Phase 3 Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) Completed
Phase 2 Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT Completed
Phase 2 Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant Completed
Phase 2 Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Completed
Phase 2 A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders Completed

Show 23 more trials

Phase 2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Completed
Phase 2 Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen Completed
Phase 2 Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Completed
Phase 2 Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies Completed
Phase 2 A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies Completed
Phase 2 A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative Completed
Phase 2 Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support Completed
Phase 2 Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation Completed
Phase 2 Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation Completed
Phase 2 Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation Completed
Phase 2 Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease Completed
Phase 2 Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy Completed
Phase 2 Phase II Trial of Pentostatin and Targeted Busulfan Completed
Phase 2 Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide Completed
Phase 2 Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies Completed
Phase 2 Cytokine Induced Killer (CIK) Cells In Leukemia Patients Completed
Phase 1 Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies Completed
Phase 1 Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction Completed
Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment Completed
Phase 1 A Study Of PF-04449913 In Select Hematologic Malignancies Completed
N/A An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies Completed
N/A Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies Completed
N/A Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT) Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Hematologic Malignancies: what the trials found

In the management of hematologic malignancies, Denosumab has been shown to significantly improve time to first on-study skeletal related events compared to standard care (p=0.010) ⁴. Other established interventions include the use of Cyclophosphamide [10, 11], Posaconazole ⁵, and Pentostatin ¹⁷. Specifically, trials involving Pentostatin reported a progression-free survival rate of 55% and an overall survival rate of 68% ¹⁷. Additionally, evidence suggests that the addition of photopheresis to Pentostatin for allogeneic stem cell transplantation resulted in a lower incidence of Grade 2-4 acute graft versus host disease (GVHD) compared to no photopheresis ¹⁵.

Recent results — preliminary, needs further review

• CC-486 was evaluated in a Phase 2 trial ¹.
• Fludarabine showed favorable outcomes for 6-month probability of survival as assessed by absence of Grade III-IV GVHD or graft failure, with zero cases of acute Grade III-IV GVHD reported ².
• An inpatient serious illness care program was evaluated in a Phase N/A trial ³.
• Tildrakizumab was evaluated in a Phase 2 trial ⁶.

For the clinician treating this condition

Denosumab is associated with a statistically significant increase in time to first skeletal related events ⁴.
Pentostatin has been associated with an overall survival rate of 68% and progression-free survival of 55% ¹⁷.
Photopheresis combined with Pentostatin was associated with lower rates of Grade 2-4 acute GVHD compared to no photopheresis ¹⁵.

AI synthesis of 8 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

1 2 Next ›

Questions about Hematologic Malignancies

Are T cell-based therapies like CAR-T effective for treating hematologic malignancies?

Yes, CAR-T cell therapy is highly effective for hematologic malignancies, with success in blood cancers like ALL, but faces challenges in solid tumors.

Full answer →

All Hematologic Malignancies Articles